These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 39172439)

  • 21. Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study.
    Wierda WG; Allan JN; Siddiqi T; Kipps TJ; Opat S; Tedeschi A; Badoux XC; Kuss BJ; Jackson S; Moreno C; Jacobs R; Pagel JM; Flinn I; Pak Y; Zhou C; Szafer-Glusman E; Ninomoto J; Dean JP; James DF; Ghia P; Tam CS
    J Clin Oncol; 2021 Dec; 39(34):3853-3865. PubMed ID: 34618601
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Venetoclax Data Prompt Rethink of CLL Therapy.
    Cancer Discov; 2018 Mar; 8(3):OF5. PubMed ID: 29382644
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
    Fürstenau M; Kater AP; Robrecht S; von Tresckow J; Zhang C; Gregor M; Thornton P; Staber PB; Tadmor T; Lindström V; Juliusson G; Janssens A; Levin MD; da Cunha-Bang C; Schneider C; Goldschmidt N; Vandenberghe E; Rossi D; Benz R; Nösslinger T; Heintel D; Poulsen CB; Christiansen I; Frederiksen H; Enggaard L; Posthuma EFM; Issa DE; Visser HPJ; Bellido M; Kutsch N; Dürig J; Stehle A; Vöhringer M; Böttcher S; Schulte C; Simon F; Fink AM; Fischer K; Holmes EE; Kreuzer KA; Ritgen M; Brüggemann M; Tausch E; Stilgenbauer S; Hallek M; Niemann CU; Eichhorst B
    Lancet Oncol; 2024 Jun; 25(6):744-759. PubMed ID: 38821083
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adding ibrutinib to frontline therapy improves outcomes in transplant-eligible patients with MCL.
    Killock D
    Nat Rev Clin Oncol; 2024 Jul; 21(7):483. PubMed ID: 38789564
    [No Abstract]   [Full Text] [Related]  

  • 25. BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax.
    Lin VS; Lew TE; Handunnetti SM; Blombery P; Nguyen T; Westerman DA; Kuss BJ; Tam CS; Roberts AW; Seymour JF; Anderson MA
    Blood; 2020 Jun; 135(25):2266-2270. PubMed ID: 32244251
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia.
    Niemann CU; Levin MD; Dubois J; Kersting S; Enggaard L; Veldhuis GJ; Mous R; Mellink CHM; Dobber JA; Poulsen CB; Frederiksen H; Janssens A; Schjødt I; Dompeling EC; Ranti J; Mattsson M; Bellido M; Tran HTT; Nasserinejad K; Kater AP
    Blood; 2021 Feb; 137(8):1117-1120. PubMed ID: 33027809
    [No Abstract]   [Full Text] [Related]  

  • 27. Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study.
    Rule S; Jurczak W; Jerkeman M; Rusconi C; Trneny M; Offner F; Caballero D; Joao C; Witzens-Harig M; Hess G; Bence-Bruckler I; Cho SG; Thieblemont C; Zhou W; Henninger T; Goldberg J; Vermeulen J; Dreyling M
    Leukemia; 2018 Aug; 32(8):1799-1803. PubMed ID: 29572505
    [No Abstract]   [Full Text] [Related]  

  • 28. Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia.
    Eide CA; Kurtz SE; Kaempf A; Long N; Agarwal A; Tognon CE; Mori M; Druker BJ; Chang BH; Danilov AV; Tyner JW
    Leukemia; 2020 Sep; 34(9):2342-2353. PubMed ID: 32094466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
    Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS
    Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical Study of Ibrutinib Combined with Venetoclax Regimen in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma].
    Yang M; Huang Y; Zhu LY; Zhang LX; Zi YM; Wang XF; Zhang Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Oct; 32(5):1414-1419. PubMed ID: 39479825
    [TBL] [Abstract][Full Text] [Related]  

  • 31. COVID-19 among fit patients with CLL treated with venetoclax-based combinations.
    Fürstenau M; Langerbeins P; De Silva N; Fink AM; Robrecht S; von Tresckow J; Simon F; Hohloch K; Droogendijk J; van der Klift M; van der Spek E; Illmer T; Schöttker B; Fischer K; Wendtner CM; Tausch E; Stilgenbauer S; Niemann CU; Gregor M; Kater AP; Hallek M; Eichhorst B
    Leukemia; 2020 Aug; 34(8):2225-2229. PubMed ID: 32601378
    [No Abstract]   [Full Text] [Related]  

  • 32. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.
    Jones JA; Mato AR; Wierda WG; Davids MS; Choi M; Cheson BD; Furman RR; Lamanna N; Barr PM; Zhou L; Chyla B; Salem AH; Verdugo M; Humerickhouse RA; Potluri J; Coutre S; Woyach J; Byrd JC
    Lancet Oncol; 2018 Jan; 19(1):65-75. PubMed ID: 29246803
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma.
    Zhou Z; Zhang L; Wang X; Li X; Li L; Fu X; Zhang X; Li Z; Sun Z; Zhang M
    Ann Hematol; 2021 Jun; 100(6):1509-1516. PubMed ID: 33900450
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does FCR have the potential to cure a subgroup of patients with chronic lymphocytic leukemia?
    Wierda WG
    Clin Adv Hematol Oncol; 2019 Apr; 17(4):214-216. PubMed ID: 31188811
    [No Abstract]   [Full Text] [Related]  

  • 35. Ibrutinib: searching for a partner drug.
    Kater AP; Brown JR
    Lancet Oncol; 2019 Jan; 20(1):3-5. PubMed ID: 30522966
    [No Abstract]   [Full Text] [Related]  

  • 36. Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy.
    Eyre TA; Walter HS; Iyengar S; Follows G; Cross M; Fox CP; Hodson A; Coats J; Narat S; Morley N; Dyer MJS; Collins GP
    Haematologica; 2019 Feb; 104(2):e68-e71. PubMed ID: 30190341
    [No Abstract]   [Full Text] [Related]  

  • 37. Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL.
    Haselager MV; Kielbassa K; Ter Burg J; Bax DJC; Fernandes SM; Borst J; Tam C; Forconi F; Chiodin G; Brown JR; Dubois J; Kater AP; Eldering E
    Blood; 2020 Dec; 136(25):2918-2926. PubMed ID: 32603412
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial.
    Kater AP; Levin MD; Dubois J; Kersting S; Enggaard L; Veldhuis GJ; Mous R; Mellink CHM; van der Kevie-Kersemaekers AF; Dobber JA; Poulsen CB; Frederiksen H; Janssens A; Schjødt I; Dompeling EC; Ranti J; Brieghel C; Mattsson M; Bellido M; Tran HTT; Nasserinejad K; Niemann CU
    Lancet Oncol; 2022 Jun; 23(6):818-828. PubMed ID: 35654052
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma.
    Chiron D; Dousset C; Brosseau C; Touzeau C; Maïga S; Moreau P; Pellat-Deceunynck C; Le Gouill S; Amiot M
    Oncotarget; 2015 Apr; 6(11):8750-9. PubMed ID: 25797245
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience.
    Innocenti I; Morelli F; Autore F; Piciocchi A; Frustaci A; Mauro FR; Schiattone L; Trentin L; Del Poeta G; Reda G; Rigolin GM; Ibatici A; Ciolli S; Coscia M; Sportoletti P; Murru R; Levato L; Gentile M; D'Arena G; Efremov DG; Tedeschi A; Scarfò L; Cuneo A; Foà R; Laurenti L
    Br J Haematol; 2019 Oct; 187(1):e8-e11. PubMed ID: 31364153
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.